Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 20 Publications

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )
Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

9 Customer Reviews

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPodXJKSzVyPUCuNFAxOzB\|IN88US=>	NEDJWWZUSU6JRWK=
IST-MEL1	NUXZTnJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\FTGpKSzVyPUCuNFAxPDB5IN88US=>	NUDsTpNqW0GQR1XS
NCI-SNU-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMECyNFch\|ryP	NIGweVhUSU6JRWK=
FADU	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfLTWM2OD1yLkCwNlA6KM7:TR?=	M1P4ZnNCVkeHUh?=
C32	M4HYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXRTWM2OD1yLkCwN\|A1KM7:TR?=	M4XrfnNCVkeHUh?=
D-566MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMECzPUDPxE1?	NYn6XJVHW0GQR1XS
LXF-289	M4LL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\4d2lEPTB;MD6wNFQyQSEQvF2=	NGf5ZpVUSU6JRWK=
HGC-27	M4DQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TqSmlEPTB;MD6wNFUyKM7:TR?=	MWPTRW5ITVJ?
RPMI-7951	M1TLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVqycnNkUUN3ME2wMlAxPzF5IN88US=>	NVTwPVhwW0GQR1XS
HSC-3	NVz4fWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jxeWlEPTB;MD6wNFkzQSEQvF2=	M1PkcXNCVkeHUh?=
MIA-PaCa-2	NEPQWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHqTWM2OD1yLkCxNFA6KM7:TR?=	M1ztcXNCVkeHUh?=
KS-1	NHXkfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEGzOVUh\|ryP	M3jFbHNCVkeHUh?=
CAL-51	M4Pob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMEG0NFUh\|ryP	MmrrV2FPT0WU
MDA-MB-361	MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;mR4xKSzVyPUCuNFE1QTVizszN	MoDFV2FPT0WU
TI-73	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrpTWM2OD1yLkCxO\|k3KM7:TR?=	Mnu3V2FPT0WU
AGS	NEDPRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWf1Row1UUN3ME2wMlAyQTN6IN88US=>	MYDTRW5ITVJ?
NCI-H460	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEG5O\|Qh\|ryP	NW\QS5FoW0GQR1XS
A204	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DyXWlEPTB;MD6wNlI1QSEQvF2=	M1mz[XNCVkeHUh?=
CHL-1	NWPaV5hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEKyOVEh\|ryP	MoTXV2FPT0WU
DU-4475	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjxWWRKSzVyPUCuNFIzPjFizszN	NGTZUVBUSU6JRWK=
CGTH-W-1	NEnWXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorsTWM2OD1yLkCyN\|Q6KM7:TR?=	NX;idpY6W0GQR1XS
HCC2218	M2e0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PRdmlEPTB;MD6wNlQ6PCEQvF2=	NVjtc3NjW0GQR1XS
A2780	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfj[YNKSzVyPUCuNFI2OzFizszN	NX;XR3oxW0GQR1XS
NCI-H720	NUHpdmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGSzZnNKSzVyPUCuNFI2PDZizszN	MWDTRW5ITVJ?
NCI-N87	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{P1SGlEPTB;MD6wNlU6OyEQvF2=	NXPDXFhsW0GQR1XS
CHP-212	M4CzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLpTWM2OD1yLkCyOlI5KM7:TR?=	MmjvV2FPT0WU
NCI-H23	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfKTWM2OD1yLkCyOlY2KM7:TR?=	NWCxco1KW0GQR1XS
D-263MG	MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEK3PFYh\|ryP	MofoV2FPT0WU
ME-180	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFj5fFdKSzVyPUCuNFI5QTFizszN	MV\TRW5ITVJ?
SW982	NEDlbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvHSFRKSzVyPUCuNFI6QTlizszN	NVXWSZU{W0GQR1XS
OE19	NEHBSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq2SYVVUUN3ME2wMlA{ODd5IN88US=>	MWfTRW5ITVJ?
SK-LU-1	M4n1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXlTWM2OD1yLkCzNFgzKM7:TR?=	M1HYb3NCVkeHUh?=
H4	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[xZYVKSzVyPUCuNFMxQSEQvF2=	MWLTRW5ITVJ?
HT-144	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLsTWM2OD1yLkCzNFk{KM7:TR?=	M1\vcXNCVkeHUh?=
SK-UT-1	NFPrRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjob4VKSzVyPUCuNFMyPzhizszN	MkOwV2FPT0WU
D-336MG	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGWydFlKSzVyPUCuNFM{ODlizszN	NU\uSW5sW0GQR1XS
MDA-MB-175-VII	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\wU2tKSzVyPUCuNFM{PTRizszN	MnrCV2FPT0WU
GAMG	NG\mW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILDRmVKSzVyPUCuNFM1OzVizszN	NYjxWHUxW0GQR1XS
CP50-MEL-B	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\QSmVKSzVyPUCuNFM1PSEQvF2=	MYDTRW5ITVJ?
OVCAR-5	M{Hndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMEO0PEDPxE1?	M3rqWXNCVkeHUh?=
SK-MES-1	NH3O[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEO2NFYh\|ryP	NEexfplUSU6JRWK=
VM-CUB-1	M4LtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV34cXU1UUN3ME2wMlA{PjV5IN88US=>	MVnTRW5ITVJ?
WM-115	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzZdm9FUUN3ME2wMlA{PzZ{IN88US=>	MWnTRW5ITVJ?
DSH1	NXi5c3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonUTWM2OD1yLkCzPFA4KM7:TR?=	NV20dG9tW0GQR1XS
Becker	M{jyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm[5TWM2OD1yLkCzPFg2KM7:TR?=	M2LQfHNCVkeHUh?=
SW962	NHzIWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLaTWM2OD1yLkCzPVQ2KM7:TR?=	NYm2WlZZW0GQR1XS
TYK-nu	M{\ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnl[ZdPUUN3ME2wMlA{QTh3IN88US=>	NIrRWJNUSU6JRWK=
HO-1-N-1	NI\nXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMESwNlEh\|ryP	NFPDdWZUSU6JRWK=
T98G	M1PTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMESxNFMh\|ryP	MnK2V2FPT0WU
ACN	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jyUWlEPTB;MD6wOFE3OiEQvF2=	NXvoPFBFW0GQR1XS
SW780	NImyfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHTTWM2OD1yLkC0NlA{KM7:TR?=	M3;GPXNCVkeHUh?=
Detroit562	NEftNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TVVmlEPTB;MD6wOFI{QSEQvF2=	MXfTRW5ITVJ?
BB49-HNC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljKTWM2OD1yLkC0NlQ{KM7:TR?=	MVjTRW5ITVJ?
HN	NF23XWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIriXlBKSzVyPUCuNFQzPzJizszN	NXzUVpY5W0GQR1XS
H9	Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPUN3JKSzVyPUCuNFQ{PzFizszN	MUnTRW5ITVJ?
VA-ES-BJ	NHrCWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTTb5oyUUN3ME2wMlA1PDR5IN88US=>	NFvuW2RUSU6JRWK=
MEL-JUSO	NGHJXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LvUGlEPTB;MD6wOFQ4PSEQvF2=	M3fX[HNCVkeHUh?=
BT-474	NH;STHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHkTWM2OD1yLkC0OUDPxE1?	MmTCV2FPT0WU
CaR-1	NVr4PGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkW4TWM2OD1yLkC0OVQ6KM7:TR?=	MnO3V2FPT0WU
PSN1	MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMES2NFMh\|ryP	NHzGVo5USU6JRWK=
KYSE-510	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMES2OFkh\|ryP	NVfHUo9VW0GQR1XS
KP-4	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMES3OVMh\|ryP	MXXTRW5ITVJ?
KYSE-410	NILGNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMES3O\|Ih\|ryP	NHnRUXdUSU6JRWK=
G-402	NEnFbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fXTWlEPTB;MD6wOFc5QSEQvF2=	NX6zblVZW0GQR1XS
DOK	NUW2b2JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jacGlEPTB;MD6wOFkxOiEQvF2=	MUTTRW5ITVJ?
COR-L88	NEj3fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVy2WGNlUUN3ME2wMlA1QTF{IN88US=>	MkexV2FPT0WU
SKG-IIIa	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXtTWM2OD1yLkC0PVg3KM7:TR?=	MmK5V2FPT0WU
AN3-CA	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LRd2lEPTB;MD6wOUDPxE1?	NHX6Z\|ZUSU6JRWK=
SW48	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLIPJI1UUN3ME2wMlA2ODN7IN88US=>	MUnTRW5ITVJ?
YKG-1	NG\oNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nK[GlEPTB;MD6wOVA4OSEQvF2=	MX;TRW5ITVJ?
KYSE-150	M3PyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT2TWM2OD1yLkC1NlM2KM7:TR?=	NHryZ5lUSU6JRWK=
HuO-3N1	M1\Bemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYe3bWltUUN3ME2wMlA2OjN5IN88US=>	NHvxVJhUSU6JRWK=
LB1047-RCC	NITFTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nicmlEPTB;MD6wOVI6PiEQvF2=	NUW5XoJJW0GQR1XS
NCI-H2030	NETWcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMEW0NVQh\|ryP	MkLyV2FPT0WU
YH-13	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjRfIpbUUN3ME2wMlA2PzJ{IN88US=>	NGn3NHNUSU6JRWK=
5637	NIrKfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq1XoFKSzVyPUCuNFU4PCEQvF2=	MWjTRW5ITVJ?
LOXIMVI	M1y1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXlOZhKSzVyPUCuNFU5PzJizszN	M2n6Z3NCVkeHUh?=
GT3TKB	NH7jeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPPepNOUUN3ME2wMlA2QTR{IN88US=>	NHToSFBUSU6JRWK=
TCCSUP	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDkPVh{UUN3ME2wMlA2QTZ2IN88US=>	NWj2[WI3W0GQR1XS
EPLC-272H	NX[xS5ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fqSWlEPTB;MD6wOlIxPSEQvF2=	NF\lSmtUSU6JRWK=
LU-99A	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwME[yN\|ch\|ryP	MnXMV2FPT0WU
NCI-H1755	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7VTm92UUN3ME2wMlA3OzRzIN88US=>	M1PwfHNCVkeHUh?=
KM12	MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfUTWM2OD1yLkC2N\|Q5KM7:TR?=	MkT4V2FPT0WU
SF295	NFHW[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwME[0OVIh\|ryP	NUfvOWZbW0GQR1XS
MZ2-MEL	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DWfWlEPTB;MD6wOlU2OyEQvF2=	MYXTRW5ITVJ?
HEC-1	M{DwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LUN2lEPTB;MD6wOlU5QCEQvF2=	NWLCV4MxW0GQR1XS
SW684	M3i1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwME[1PVEh\|ryP	M1XtNXNCVkeHUh?=
SF539	NWm4WYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwME[2PFEh\|ryP	NFK3WXJUSU6JRWK=
GMS-10	M4X4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXH6ZnMyUUN3ME2wMlA3Pjl7IN88US=>	MnjmV2FPT0WU
MV-4-11	NU\KTHcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vmOGlEPTB;MD6wOlgxOyEQvF2=	MkHlV2FPT0WU
HT-29	NXTFOnlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S4bGlEPTB;MD6wOlkyQSEQvF2=	M3HkenNCVkeHUh?=
23132-87	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInLZ\|FKSzVyPUCuNFY6PSEQvF2=	MVvTRW5ITVJ?
SW620	M33QWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGS0N2FKSzVyPUCuNFcxOjZizszN	NXfTNHdXW0GQR1XS
HCC1806	NUXDPWFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUK2VmI{UUN3ME2wMlA4OTNzIN88US=>	MWTTRW5ITVJ?
Hs-578-T	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHO[ZhMUUN3ME2wMlA4OjB6IN88US=>	M4TTVXNCVkeHUh?=
A2058	NWW1codET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEeyNlgh\|ryP	MXvTRW5ITVJ?
MEL-HO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjvb5JGUUN3ME2wMlA4OjV3IN88US=>	NYSyO4ZPW0GQR1XS
HCC2998	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\5UFRKSzVyPUCuNFc{PDdizszN	Ml;4V2FPT0WU
HuO9	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMEe1PFkh\|ryP	M4\odXNCVkeHUh?=
CAL-39	NF24TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ewNWlEPTB;MD6wO\|c3PiEQvF2=	M4jENnNCVkeHUh?=
M14	MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMEe5NVMh\|ryP	NWLwUVZOW0GQR1XS
BFTC-909	NV30OVJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHi[ZB5UUN3ME2wMlA4QTZ7IN88US=>	M3P3WHNCVkeHUh?=
TE-11	M3rLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HFOGlEPTB;MD6wO\|k6PiEQvF2=	MWrTRW5ITVJ?
TGBC1TKB	NX;1eGQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{f3eGlEPTB;MD6wPFA1OyEQvF2=	M2[3XHNCVkeHUh?=
L-363	NGfvZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMEiyNFYh\|ryP	M37JZXNCVkeHUh?=
A431	MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEiyNUDPxE1?	NXXOXHhyW0GQR1XS
MKN45	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzHTWM2OD1yLkC4NlE6KM7:TR?=	NUHSXpZYW0GQR1XS
HT-1080	M4q4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn6TWM2OD1yLkC4OFM6KM7:TR?=	MkHuV2FPT0WU
OVCAR-8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEi2NlIh\|ryP	MUHTRW5ITVJ?
LCLC-97TM1	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zRXmlEPTB;MD6wPFczQCEQvF2=	NWryTXQ5W0GQR1XS
M059J	NFTHeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnm1TWM2OD1yLkC5NFI4KM7:TR?=	MVzTRW5ITVJ?
SK-MEL-2	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7ZSGpKSzVyPUCuNFkxPiEQvF2=	MXnTRW5ITVJ?
TE-1	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnGXJVKSzVyPUCuNFkzODRizszN	MkXWV2FPT0WU
KYSE-180	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7FXFV1UUN3ME2wMlA6OjZ{IN88US=>	M1jqdHNCVkeHUh?=
D-247MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIKwbIRKSzVyPUCuNFk1PTVizszN	NEHKd4pUSU6JRWK=
8-MG-BA	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7STlFKSzVyPUCuNFk1PzJizszN	MnjCV2FPT0WU
NCI-H1792	NGew[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfPVlFHUUN3ME2wMlA6PjF6IN88US=>	MoDOV2FPT0WU
MCF7	NFLwPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfvRVdVUUN3ME2wMlA6Pjd5IN88US=>	NYO0[5lZW0GQR1XS
NCI-H2122	NVTrNIF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrlTWM2OD1yLkC5O\|Q2KM7:TR?=	NU\BdmVuW0GQR1XS
EFO-27	M332b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMEm5PVch\|ryP	MXXTRW5ITVJ?
LB2241-RCC	NX70Oo56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jSRWlEPTB;MD6xNFA2PCEQvF2=	NILTcVhUSU6JRWK=
SN12C	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7yZ2E4UUN3ME2wMlExOTB5IN88US=>	NVXBZWhVW0GQR1XS
A498	M3\ZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMUCxPEDPxE1?	NXHpc2dHW0GQR1XS
PANC-03-27	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFm2Z3RKSzVyPUCuNVAzQDZizszN	MV;TRW5ITVJ?
NCI-H1581	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zhfGlEPTB;MD6xNFI6KM7:TR?=	NGHDVXhUSU6JRWK=
U-87-MG	NHP5PW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorUTWM2OD1yLkGwN\|A4KM7:TR?=	NYP3OnpZW0GQR1XS
G-401	NYrUbFJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMUCzOVMh\|ryP	NF\tfmFUSU6JRWK=
SiHa	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HUXmlEPTB;MD6xNFQ5PiEQvF2=	M2HzfnNCVkeHUh?=
U251	NGXaTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TLd2lEPTB;MD6xNFUzPSEQvF2=	M2rTe3NCVkeHUh?=
MMAC-SF	MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD5UHdKSzVyPUCuNVA2OzFizszN	Mn3LV2FPT0WU
BB65-RCC	NVmxZmxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fnW2lEPTB;MD6xNFU2PCEQvF2=	NUH0[IxSW0GQR1XS
NKM-1	NYDKPHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DF[2lEPTB;MD6xNFY3PiEQvF2=	MX3TRW5ITVJ?
HD-MY-Z	M3PQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnuwTWM2OD1yLkGwPFc{KM7:TR?=	NVHVfZJYW0GQR1XS
TGBC11TKB	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFj5ZVVKSzVyPUCuNVA6ODNizszN	MWfTRW5ITVJ?
COLO-679	NXXxW5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELy[3lKSzVyPUCuNVEzOTFizszN	M4L2UXNCVkeHUh?=
TE-8	NFT4[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXKTWM2OD1yLkGxNlY1KM7:TR?=	NVz3dpQxW0GQR1XS
SK-MEL-28	NXnJNHRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvFW3Z[UUN3ME2wMlEyOzJzIN88US=>	M2XDN3NCVkeHUh?=
SH-4	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULQW4hRUUN3ME2wMlEyOzV4IN88US=>	NFTaRY9USU6JRWK=
KALS-1	NF\lU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\HTWM2OD1yLkGxN\|k{KM7:TR?=	NH\6U\|lUSU6JRWK=
RKO	M4\sSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\oXW1KSzVyPUCuNVE4PjRizszN	M3O0RnNCVkeHUh?=
OMC-1	NX7qdWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;OPWdKSzVyPUCuNVE4QTdizszN	NGDoeYVUSU6JRWK=
BT-549	M4jvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:0TWM2OD1yLkGxO\|k6KM7:TR?=	NH:1fWNUSU6JRWK=
NCI-H28	NXfMTnF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMUG4NVch\|ryP	MoTaV2FPT0WU
RXF393	M{\id2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m0NmlEPTB;MD6xNVk5OiEQvF2=	NFm3SYtUSU6JRWK=
COLO-829	NWTCUVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETmZpFKSzVyPUCuNVIxODVizszN	M3:2VnNCVkeHUh?=
HMV-II	NUTJUW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE[1WWtKSzVyPUCuNVIxOiEQvF2=	MmLlV2FPT0WU
SW1990	M3;ReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvjUoxKSzVyPUCuNVIyPTdizszN	MXXTRW5ITVJ?
NCI-H1437	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PtT2lEPTB;MD6xNlE2PyEQvF2=	MX\TRW5ITVJ?
SNB75	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S3e2lEPTB;MD6xNlE3QSEQvF2=	M2nIUnNCVkeHUh?=
EW-3	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInYW3BKSzVyPUCuNVI3PjFizszN	NUnUSoo2W0GQR1XS
SAS	M3n5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T5eWlEPTB;MD6xNlY6KM7:TR?=	MVPTRW5ITVJ?
NCI-H1666	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMUK3O\|Qh\|ryP	MYLTRW5ITVJ?
A375	MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGG3V3JKSzVyPUCuNVI4PzhizszN	MV7TRW5ITVJ?
CAMA-1	NHywT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zGdGlEPTB;MD6xNlkzPCEQvF2=	M{XrZnNCVkeHUh?=
HuP-T4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\xVWlEPTB;MD6xNlk1OyEQvF2=	M1nTW3NCVkeHUh?=
NCI-H292	MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zSWmlEPTB;MD6xN\|EyKM7:TR?=	M{DBOnNCVkeHUh?=
PC-14	NHn5NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DI[mlEPTB;MD6xN\|IyOSEQvF2=	M3:2RXNCVkeHUh?=
BPH-1	NYLMS2xzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nFUWlEPTB;MD6xN\|QyKM7:TR?=	MmDLV2FPT0WU
GAK	NXXFNGNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nqW2lEPTB;MD6xN\|U3PyEQvF2=	M4e0bnNCVkeHUh?=
VMRC-RCZ	NWLacFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PUfmlEPTB;MD6xN\|c3OiEQvF2=	NHrsSXZUSU6JRWK=
SK-MEL-24	M4DXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMUO4O{DPxE1?	MY\TRW5ITVJ?
LB831-BLC	M1;sNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMUO4PFMh\|ryP	MorKV2FPT0WU
NCI-H2452	M4Lhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TYWmlEPTB;MD6xN\|k2PiEQvF2=	MYjTRW5ITVJ?
RT-112	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMUSwN\|Uh\|ryP	NYDFdYJCW0GQR1XS
GP5d	NXTES3FjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\uO5BKSzVyPUCuNVQyODRizszN	MYXTRW5ITVJ?
LC-2-ad	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfZVGREUUN3ME2wMlE1OTJzIN88US=>	MoXrV2FPT0WU
MPP-89	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTieY1KSzVyPUCuNVQyOjVizszN	NIr0PHBUSU6JRWK=
NUGC-3	M{i3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMUS0O\|gh\|ryP	NFnE[FJUSU6JRWK=
GI-1	NIXjXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfRZ2lKSzVyPUCuNVQ2PThizszN	M1nJPXNCVkeHUh?=
HCC1419	NYfNblRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmT5TWM2OD1yLkG0OVc3KM7:TR?=	MYDTRW5ITVJ?
SW1573	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rI[mlEPTB;MD6xOFc2QCEQvF2=	MkTDV2FPT0WU
NCI-H2347	NEXwdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzheI5KSzVyPUCuNVQ5OzlizszN	MVPTRW5ITVJ?
Mewo	M1;TR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfTTWM2OD1yLkG0PFg6KM7:TR?=	Mn;KV2FPT0WU
639-V	NE\LcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nubGlEPTB;MD6xOVAyOyEQvF2=	NXnyTpNHW0GQR1XS
AsPC-1	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMUWyNlUh\|ryP	NULxXHRHW0GQR1XS
NCI-H1648	NH:2WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDzTGZKSzVyPUCuNVUzOzJizszN	M1nqXHNCVkeHUh?=
786-0	NHfHTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;yTWM2OD1yLkG1N\|gyKM7:TR?=	MoP2V2FPT0WU
ETK-1	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zrZ2lEPTB;MD6xOVkh\|ryP	MkD1V2FPT0WU
BxPC-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHpZYlKSzVyPUCuNVU6PjZizszN	NY\zcpJEW0GQR1XS
CAL-62	M{TzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\KTWM2OD1yLkG2NVY6KM7:TR?=	NFXieYFUSU6JRWK=
HCC1937	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMU[yO\|Uh\|ryP	M2jpZnNCVkeHUh?=
NCI-H1299	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrTbm1{UUN3ME2wMlE3Ojh3IN88US=>	Mm\PV2FPT0WU
SW1088	NVfISYVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMU[0NVMh\|ryP	NFzq[ZVUSU6JRWK=
FTC-133	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMU[1OEDPxE1?	M3\VcHNCVkeHUh?=
OC-314	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mly4TWM2OD1yLkG2Olkh\|ryP	NHXmc4FUSU6JRWK=
SCC-9	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnBeplFUUN3ME2wMlE3PzF4IN88US=>	NYHjNlZZW0GQR1XS
HT-1376	NUjjPFZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjWSnpYUUN3ME2wMlE3QTN4IN88US=>	Ml7DV2FPT0WU
U-2-OS	NHnLWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fUfmlEPTB;MD6xO\|E4OyEQvF2=	MkPUV2FPT0WU
COLO-824	M1nO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvRdmZKSzVyPUCuNVczQTRizszN	M{HJV3NCVkeHUh?=
BB30-HNC	NYjYOIRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIH5RpVKSzVyPUCuNVc{OyEQvF2=	Mn\vV2FPT0WU
NCI-H2087	NF2wbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUGyXWpWUUN3ME2wMlE4OzZ6IN88US=>	NGezZ4FUSU6JRWK=
NCI-H2170	NIf3ZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkS0TWM2OD1yLkG3OVM3KM7:TR?=	NIXxUGdUSU6JRWK=
SK-OV-3	NWTqfVVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH2VG1tUUN3ME2wMlE4PTdzIN88US=>	NUjZe45ZW0GQR1XS
MZ7-mel	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33TR2lEPTB;MD6xO\|Y1QSEQvF2=	MVvTRW5ITVJ?
NCI-H650	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT1U3ZKSzVyPUCuNVc3QDJizszN	NV7TXZBoW0GQR1XS
KOSC-2	NEfqOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrSR3RKSzVyPUCuNVc4OzRizszN	MmXoV2FPT0WU
SCC-4	M4WxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkCwTWM2OD1yLkG3O\|c4KM7:TR?=	NYPJZWRbW0GQR1XS
MDA-MB-157	NIS3R29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\ReVZxUUN3ME2wMlE5ODh{IN88US=>	NGjCenBUSU6JRWK=
KYSE-520	M{jtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXubo5pUUN3ME2wMlE5OiEQvF2=	NIPNflhUSU6JRWK=
LK-2	NFXue5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XpfmlEPTB;MD6xPFMxOyEQvF2=	M1v5bnNCVkeHUh?=
KNS-81-FD	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjEeIJKSzVyPUCuNVg{QTRizszN	NHHOTZFUSU6JRWK=
IGROV-1	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHq1[5BKSzVyPUCuNVg1PDNizszN	MXLTRW5ITVJ?
DEL	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDEdlhCUUN3ME2wMlE5PDVizszN	MX3TRW5ITVJ?
NCI-H1395	NELTbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMUi2PFIh\|ryP	NFjENlVUSU6JRWK=
JEG-3	NEDXS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n0OmlEPTB;MD6xPFcxPSEQvF2=	M4LSWXNCVkeHUh?=
BCPAP	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HyPWlEPTB;MD6xPFg4OiEQvF2=	MlzmV2FPT0WU
CAL-27	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;qZ2hKSzVyPUCuNVkxOjJizszN	M4[2fHNCVkeHUh?=
RD	NIf4SI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMUmxNVMh\|ryP	M4TROXNCVkeHUh?=
RVH-421	NHmwOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLIOpo1UUN3ME2wMlE6OTF4IN88US=>	NYjqTpF4W0GQR1XS
Capan-2	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrJZZlpUUN3ME2wMlE6OjV4IN88US=>	NXXMZolYW0GQR1XS
COLO-680N	MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XhbmlEPTB;MD6xPVM3PCEQvF2=	MWjTRW5ITVJ?
NCI-H1650	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMkCwOVch\|ryP	M2jsVXNCVkeHUh?=
SBC-5	NYnkUJhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMkCxNVgh\|ryP	MVTTRW5ITVJ?
U031	NFfi[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDxPG5iUUN3ME2wMlIxPTR5IN88US=>	M2raV3NCVkeHUh?=
S-117	M1e4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIX6XVRKSzVyPUCuNlA2PjRizszN	Mn3jV2FPT0WU
DoTc2-4510	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fBXGlEPTB;MD6yNFc3QSEQvF2=	NVHCOolLW0GQR1XS
AM-38	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMkC4OFgh\|ryP	NVj4VJdJW0GQR1XS
A172	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjtOW83UUN3ME2wMlIyODJ{IN88US=>	MVXTRW5ITVJ?
HPAF-II	NXjHTldjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMkGyOlQh\|ryP	M1v2OnNCVkeHUh?=
769-P	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M362[GlEPTB;MD6yNVI5KM7:TR?=	M3XqO3NCVkeHUh?=
MFE-280	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjlO2xjUUN3ME2wMlIyOjl6IN88US=>	MX7TRW5ITVJ?
TE-9	NX32ZnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1e3b2lEPTB;MD6yNVc5PiEQvF2=	NHHndY5USU6JRWK=
C2BBe1	NXfBZWJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XFZWlEPTB;MD6yNlE6KM7:TR?=	NFjad3BUSU6JRWK=
EoL-1-cell	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zhWmlEPTB;MD6yNlIxOyEQvF2=	NX3aU5lnW0GQR1XS
G-361	NGnLfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMkK2PFIh\|ryP	NVjEd5IyW0GQR1XS
KYSE-270	M1TyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXmTWM2OD1yLkKzNFg1KM7:TR?=	MnP1V2FPT0WU
TK10	NWL1NGdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2i3W2lEPTB;MD6yN\|EyPyEQvF2=	NVzsNXVlW0GQR1XS
ML-2	NIL4eVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoC2TWM2OD1yLkKzNVE6KM7:TR?=	NI\uXWNUSU6JRWK=
MHH-ES-1	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M120WmlEPTB;MD6yN\|Y5OSEQvF2=	NFL2VYNUSU6JRWK=
BHY	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjwTWM2OD1yLkKzOlkyKM7:TR?=	NIXD[ZZUSU6JRWK=
LS-513	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjYVYZKSzVyPUCuNlM6PjFizszN	M{DyS3NCVkeHUh?=
COLO-678	NYXFTHdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrPfZc1UUN3ME2wMlI1ODR2IN88US=>	Mmm2V2FPT0WU
NCI-H747	NUjCfGptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fVO2lEPTB;MD6yOFE3QSEQvF2=	NUDwR5RmW0GQR1XS
K5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HOWmlEPTB;MD6yOFM5KM7:TR?=	NEnWb4RUSU6JRWK=
OS-RC-2	NWr3Vpg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4ricWlEPTB;MD6yOFUxQSEQvF2=	MULTRW5ITVJ?
KINGS-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf2TWM2OD1yLkK0OVI6KM7:TR?=	MmT1V2FPT0WU
SCC-25	NVrHXVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHuVll{UUN3ME2wMlI1PTZ\|IN88US=>	NHnufmxUSU6JRWK=
CAPAN-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{G3V2lEPTB;MD6yOFc5OyEQvF2=	MoPCV2FPT0WU
ESS-1	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYK5RWxMUUN3ME2wMlI1QDB3IN88US=>	MlnBV2FPT0WU
TE-6	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjOW3Z6UUN3ME2wMlI2PzVizszN	MkPRV2FPT0WU
LB2518-MEL	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEf6WZVKSzVyPUCuNlU4PzdizszN	MVXTRW5ITVJ?
COLO-800	NIe1OI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MomwTWM2OD1yLkK1PFEzKM7:TR?=	MlL3V2FPT0WU
LU-134-A	M4Dpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXP5VWtvUUN3ME2wMlI3OTN4IN88US=>	MXjTRW5ITVJ?
NCI-H1155	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXXcIlOUUN3ME2wMlI3OTZ{IN88US=>	M3foPHNCVkeHUh?=
MFM-223	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMk[zOlMh\|ryP	MVvTRW5ITVJ?
HTC-C3	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7TclNwUUN3ME2wMlI3PTB4IN88US=>	M2DVfnNCVkeHUh?=
HCT-116	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMk[1PVkh\|ryP	MmHLV2FPT0WU
Ca-Ski	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LqfWlEPTB;MD6yOlY4QCEQvF2=	NHu1d2xUSU6JRWK=
SBC-1	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPle2duUUN3ME2wMlI3PzR{IN88US=>	NFTWcGNUSU6JRWK=
NB69	NEPsRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HWRmlEPTB;MD6yO\|A5PyEQvF2=	NGj0XlVUSU6JRWK=
J82	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3Dd2JxUUN3ME2wMlI4OjZ3IN88US=>	Mn3MV2FPT0WU
U-118-MG	NWPxfWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMke1O\|kh\|ryP	MnzlV2FPT0WU
NCI-H1355	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnETWM2OD1yLkK4NFc1KM7:TR?=	M37kVnNCVkeHUh?=
NCI-H1048	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rSNmlEPTB;MD6yPFk2PiEQvF2=	Ml35V2FPT0WU
SW954	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXu1OJFJUUN3ME2wMlI6OjJ5IN88US=>	M4PaVXNCVkeHUh?=
NMC-G1	M2Tp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LER2lEPTB;MD6yPVI4PyEQvF2=	NEjTc49USU6JRWK=
SW1710	NWDjW5M{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vnfWlEPTB;MD6yPVQ6PCEQvF2=	MXjTRW5ITVJ?
KY821	NX7WTmZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXvSZZKSzVyPUCuNlk5PzJizszN	MknhV2FPT0WU
HCC38	NWPK[XBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPhRm9KSzVyPUCuN\|AxPzhizszN	Mly1V2FPT0WU
NCI-SNU-5	NWHpfmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLofIlKSzVyPUCuN\|A2PCEQvF2=	NGjxWJpUSU6JRWK=
ES8	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITufJNKSzVyPUCuN\|A4QDRizszN	MX3TRW5ITVJ?
COLO-792	NXftb\|A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{KxbmlEPTB;MD6zNVI2OSEQvF2=	NIiwcFVUSU6JRWK=
BFTC-905	M1zjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnvVWdKSzVyPUCuN\|E2OjFizszN	MlvuV2FPT0WU
ChaGo-K-1	NFniVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn0NmRKSzVyPUCuN\|E4OTVizszN	MY\TRW5ITVJ?
Daoy	NUPkVG1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIT2WWZKSzVyPUCuN\|E4OjNizszN	NXH5PGRkW0GQR1XS
SJSA-1	NYf1fZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjrV2ZOUUN3ME2wMlMyQDR5IN88US=>	M4LVXnNCVkeHUh?=
KNS-62	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnsN5VZUUN3ME2wMlMzODh6IN88US=>	NVPCeGRKW0GQR1XS
CAKI-1	M3HNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnidVlrUUN3ME2wMlMzOTFzIN88US=>	NHfRNpFUSU6JRWK=
UACC-62	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fpfWlEPTB;MD6zNlIzPyEQvF2=	NHjORY9USU6JRWK=
HuCCT1	MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HXZ2lEPTB;MD6zNlI5OyEQvF2=	NGXVb29USU6JRWK=
CTB-1	NHO5WYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHNNHBKSzVyPUCuN\|I4PTNizszN	MknPV2FPT0WU
NTERA-S-cl-D1	NHz1UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIiyN5FKSzVyPUCuN\|I5OzZizszN	M3vj[XNCVkeHUh?=
T-24	MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwM{OxOVkh\|ryP	MXvTRW5ITVJ?
KYSE-70	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL2[oFKSzVyPUCuN\|MzQDNizszN	NFz1cIJUSU6JRWK=
SW626	M{H6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTETWM2OD1yLkOzOVMzKM7:TR?=	NW\WZlRwW0GQR1XS
LB996-RCC	NITZVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXuTGxKSzVyPUCuN\|M3OTlizszN	MUfTRW5ITVJ?
DMS-273	NVz6fndiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwM{O5NVYh\|ryP	MU\TRW5ITVJ?
SW1783	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL3PHdKSzVyPUCuN\|M6QTdizszN	MWHTRW5ITVJ?
KU812	M4qyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwM{SwN\|gh\|ryP	MnzYV2FPT0WU
HSC-2	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTDboxKSzVyPUCuN\|QxPTNizszN	NFXHcJdUSU6JRWK=
A3-KAW	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HUR2lEPTB;MD6zOFE3OiEQvF2=	MV;TRW5ITVJ?
COLO-684	NGfzXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrPTWM2OD1yLkO0OVAyKM7:TR?=	MVLTRW5ITVJ?
NCI-H2405	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13WTmlEPTB;MD6zOFY{OSEQvF2=	M4TyTHNCVkeHUh?=
NCI-H2228	NYi4PZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml2xTWM2OD1yLkO1N\|U4KM7:TR?=	NUXPT\|JXW0GQR1XS
NB13	NHr2PHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rwVGlEPTB;MD6zOlgzQSEQvF2=	M3vUdHNCVkeHUh?=
no-11	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXmSXoyUUN3ME2wMlM3QTVizszN	M3GzcHNCVkeHUh?=
DK-MG	NUjhc3FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7jO\|ZKSzVyPUCuN\|cyQDhizszN	MmDpV2FPT0WU
NBsusSR	M{noT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme4TWM2OD1yLkO3Nlg2KM7:TR?=	NXfJV\|d1W0GQR1XS
KP-N-YS	M3vISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn2TWNKSzVyPUCuN\|c1PjNizszN	NGTj[YRUSU6JRWK=
CFPAC-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MniyTWM2OD1yLkO3OVE5KM7:TR?=	MXLTRW5ITVJ?
KARPAS-45	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojTTWM2OD1yLkO3PFYzKM7:TR?=	NEXBTHhUSU6JRWK=
NCI-H1793	MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD1eVBbUUN3ME2wMlM5PTFizszN	M1rLSHNCVkeHUh?=
HCE-T	NWTMSXJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFr4VYxKSzVyPUCuN\|g3ODNizszN	NF72bZhUSU6JRWK=
NCI-H520	NELadphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv5TWM2OD1yLkO4O\|A{KM7:TR?=	NEfze\|dUSU6JRWK=
HCC2157	MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DM[GlEPTB;MD6zPFc5OSEQvF2=	MYHTRW5ITVJ?
EW-18	NU\6SpVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXO4e45sUUN3ME2wMlM5QTRzIN88US=>	MXrTRW5ITVJ?
RO82-W-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGexXVlKSzVyPUCuN\|k3QTlizszN	MV;TRW5ITVJ?
HuP-T3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnr4TWM2OD1yLkSwNVQ{KM7:TR?=	NEjQ[\|FUSU6JRWK=
PANC-10-05	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTi[YV5UUN3ME2wMlQyOTdizszN	MnjtV2FPT0WU
NCI-H1703	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLPdnB5UUN3ME2wMlQyPDR4IN88US=>	NVjkNmF5W0GQR1XS
TE-10	NWPRblZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HyN2lEPTB;MD60NVQ1PyEQvF2=	MkOwV2FPT0WU
HOS	NHe0c\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIq4coJKSzVyPUCuOFE3QDJizszN	MmTmV2FPT0WU
LN-405	NGHiXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXu2bJJKUUN3ME2wMlQyPjh5IN88US=>	MWHTRW5ITVJ?
A427	NWrqN3lZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mke0TWM2OD1yLkSxPVgyKM7:TR?=	Moq2V2FPT0WU
CAL-12T	NXm1UFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGL4dGVKSzVyPUCuOFI4QCEQvF2=	MX7TRW5ITVJ?
SW756	NYjnWXVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfqS\|ZKSzVyPUCuOFQyQDNizszN	MV7TRW5ITVJ?
YAPC	NV21c5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXmTW1wUUN3ME2wMlQ2ODhizszN	NWG3OWpjW0GQR1XS
GOTO	M3LqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwNEWxOkDPxE1?	MmPwV2FPT0WU
C3A	NWrnfmFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf3OoN{UUN3ME2wMlQ2PDN5IN88US=>	MnPPV2FPT0WU
UM-UC-3	NH7rN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvRTWM2OD1yLkS1OFch\|ryP	MljhV2FPT0WU
NCI-H1573	NUm2Z5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnRcppPUUN3ME2wMlQ2PTZ7IN88US=>	NVTJSHd6W0GQR1XS
LS-411N	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTYTWM2OD1yLkS2OVI4KM7:TR?=	MnXaV2FPT0WU
COR-L23	M1jpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jMN2lEPTB;MD60Olc3PCEQvF2=	M1vre3NCVkeHUh?=
HCE-4	M1PKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3YS2JKSzVyPUCuOFc1PDZizszN	Ml3wV2FPT0WU
NCI-H2291	NGjTWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rGOGlEPTB;MD60O\|g6PiEQvF2=	M1LJfXNCVkeHUh?=
A101D	MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;kTWM2OD1yLkS4NFU{KM7:TR?=	M3;0VXNCVkeHUh?=
HT-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnzNGFRUUN3ME2wMlQ5OjF5IN88US=>	M37IeHNCVkeHUh?=
HOP-62	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHt[2xKSzVyPUCuOFk5PjVizszN	NUPuTJBJW0GQR1XS
PC-3	M{TobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwNUG1NFch\|ryP	NEDPfm1USU6JRWK=
CTV-1	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHyTWM2OD1yLkWyOlY6KM7:TR?=	NFjlSpNUSU6JRWK=
PANC-08-13	NHW5N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTWPHZlUUN3ME2wMlU{OTd5IN88US=>	NWfGcpN7W0GQR1XS
CAL-120	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwNUOzPVkh\|ryP	NHnSPW1USU6JRWK=
UMC-11	M3[4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\BTWM2OD1yLkW1NlM1KM7:TR?=	NHrQTlBUSU6JRWK=
MSTO-211H	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwNUW3OlIh\|ryP	NF7Nco5USU6JRWK=
NCI-H2126	NH[2b41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwNU[4NVUh\|ryP	MlfKV2FPT0WU
SNU-C2B	NE\1OJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwNUe5O\|ch\|ryP	NUXjWY01W0GQR1XS
DBTRG-05MG	NGLLOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwNUiwOVMh\|ryP	MYrTRW5ITVJ?
MKN1	MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmriTWM2OD1yLkW4O\|g{KM7:TR?=	NV;yWJRzW0GQR1XS
ES3	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnXOpB1UUN3ME2wMlU6OTJ2IN88US=>	M1O1R3NCVkeHUh?=
OVCAR-3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LnTmlEPTB;MD61PVM1OSEQvF2=	NInFNVdUSU6JRWK=
ACHN	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Tpc2lEPTB;MD62NFU3QSEQvF2=	NHLDdXBUSU6JRWK=
SW872	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTKNlBNUUN3ME2wMlYxPzZ\|IN88US=>	MlXNV2FPT0WU
CP66-MEL	M4DnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jVdWlEPTB;MD62NFk3QSEQvF2=	NV7zZ40{W0GQR1XS
NCI-H661	NX3YbXFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XGbGlEPTB;MD62NVExPCEQvF2=	NWHFfnNoW0GQR1XS
UACC-893	NVPyUVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwNkO2PFEh\|ryP	NXizepVSW0GQR1XS
JVM-3	NH;X[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwNkO4NFQh\|ryP	MlrlV2FPT0WU
SF268	M1jJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;FS2lEPTB;MD62OFM1QSEQvF2=	NITMeVNUSU6JRWK=
OCI-AML2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHkVppVUUN3ME2wMlY2Ozl5IN88US=>	MUDTRW5ITVJ?
RPMI-8226	NXXmdo5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPxd3dKSzVyPUCuOlY{OjNizszN	M37udXNCVkeHUh?=
MKN28	Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF76c4hKSzVyPUCuOlY3OjRizszN	M3nCVHNCVkeHUh?=
MDA-MB-453	NFTIdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LqbWlEPTB;MD62O\|E5KM7:TR?=	NHnMbXdUSU6JRWK=
BV-173	NF3HbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYD6TZA5UUN3ME2wMlY5Pjd7IN88US=>	MW\TRW5ITVJ?
NCI-H358	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwNki3NlYh\|ryP	NUXlR5JmW0GQR1XS
NCI-H1651	NV7mWHl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mme3TWM2OD1yLkeg{txO	NFjrNGxUSU6JRWK=
MDA-MB-415	NWfpb5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHoTWM2OD1yLkewPFI6KM7:TR?=	NXP6Wpp1W0GQR1XS
8305C	NFjiUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkewTWM2OD1yLkeyOFk5KM7:TR?=	MXXTRW5ITVJ?
EFM-19	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfndYZ[UUN3ME2wMlc{PjdzIN88US=>	NWPHVYVNW0GQR1XS
RERF-LC-MS	NVTXcGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwN{S2NVMh\|ryP	NX3LW4ZGW0GQR1XS
A388	NXPzS3gzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkf4TWM2OD1yLke2OFY4KM7:TR?=	M1jZTXNCVkeHUh?=
GI-ME-N	NGPM[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfiTWM2OD1yLke3NlM2KM7:TR?=	MX\TRW5ITVJ?
IGR-1	NX70N256T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml6zTWM2OD1yLke5NFQ{KM7:TR?=	MVHTRW5ITVJ?
LNCaP-Clone-FGC	M37aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwOECwNFQh\|ryP	MXXTRW5ITVJ?
SK-MEL-3	NVnXWlNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHEWoF6UUN3ME2wMlgyPTB6IN88US=>	MmXzV2FPT0WU
UACC-257	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwOEKyN\|Eh\|ryP	MWXTRW5ITVJ?
OE33	NXPjfGpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TMeGlEPTB;MD64OVExOSEQvF2=	NGfuTmlUSU6JRWK=
QIMR-WIL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDWT3ZoUUN3ME2wMlg2OTRzIN88US=>	NXnCNI9pW0GQR1XS
NCI-H2009	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTLc4ZKSzVyPUCuPFU{OTFizszN	M1S5SnNCVkeHUh?=
NCI-H522	NH7vVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIj6N5VKSzVyPUCuPFc4QDNizszN	MUnTRW5ITVJ?
Saos-2	NVPKVFQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fXbWlEPTB;MD64O\|g4OSEQvF2=	NFO3VIxUSU6JRWK=
NB17	NULpV3lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zzfWlEPTB;MD64PFAzPSEQvF2=	Ml7xV2FPT0WU
D-392MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17xOGlEPTB;MD64PVM2PiEQvF2=	M3HsTHNCVkeHUh?=
SHP-77	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwOUC0PFUh\|ryP	NFz5NHNUSU6JRWK=
SK-MEL-30	M2rFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH2TWM2OD1yLkmxNVg2KM7:TR?=	NUPyXWxvW0GQR1XS
GCIY	NEWweHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moi2TWM2OD1yLkmxPFQ{KM7:TR?=	Ml;BV2FPT0WU
HCC70	NYDzWWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3Ke\|ZrUUN3ME2wMlkzODV7IN88US=>	M2jhWnNCVkeHUh?=
LU-65	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2qyTmlEPTB;MD65NlU6OSEQvF2=	MkDEV2FPT0WU
NCI-H1563	NEDjTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHGdldKSzVyPUCuPVQ5PjVizszN	MVPTRW5ITVJ?
KURAMOCHI	M{jscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f3ZWlEPTB;MD65OVE6OiEQvF2=	MnnqV2FPT0WU
PA-1	M3nWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXKxfYdlUUN3ME2wMlk2PDJ2IN88US=>	M2XnT3NCVkeHUh?=
NOS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvxTWM2OD1yLkm3OFg6KM7:TR?=	NEjpXI9USU6JRWK=
NCI-H69	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwOUe2N\|Qh\|ryP	M1PlNnNCVkeHUh?=
KYSE-450	NHvxZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPYcmhKSzVyPUCuPVg3OjZizszN	NVL3XolpW0GQR1XS
8505C	M2TvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPJTWM2OD1yLkm5PVgzKM7:TR?=	MXvTRW5ITVJ?
TGBC24TKB	M3rq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn5NodFUUN3ME2xMlAxODh2IN88US=>	MVrTRW5ITVJ?
PFSK-1	NUjmOpZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO1Sml4UUN3ME2xMlAyPDJ6IN88US=>	NILsUHlUSU6JRWK=
EKVX	NHPmW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHK1bolKSzVyPUGuNFMyOjFizszN	MULTRW5ITVJ?
RCM-1	M{LvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwMEW1NFch\|ryP	NHvu[HFUSU6JRWK=
SW900	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrYPXVKSzVyPUGuNFc5OyEQvF2=	NUHBcXc4W0GQR1XS
D-542MG	M1ywRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDrenNKSzVyPUGuNFc5PTVizszN	MUXTRW5ITVJ?
SK-PN-DW	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HaS2lEPTB;MT6xNFA2PiEQvF2=	MmLjV2FPT0WU
NCI-H727	NV;4SJpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\IT2lEPTB;MT6xNFE2PCEQvF2=	MmflV2FPT0WU
SW837	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFK5fmFKSzVyPUGuNVA6PTRizszN	MmTLV2FPT0WU
BT-20	M3\qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M12y[GlEPTB;MT6xNVIxPCEQvF2=	MVTTRW5ITVJ?
RH-18	NXG5TldbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTFwMUOxNFMh\|ryP	Mlz3V2FPT0WU
TE-12	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnRVJFRUUN3ME2xMlE{OzN\|IN88US=>	NF;5XVRUSU6JRWK=
NB10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjuRlg{UUN3ME2xMlE{OzR2IN88US=>	M17adHNCVkeHUh?=
AU565	M1XIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjTTWM2OD1zLkG1PVc{KM7:TR?=	M2HwenNCVkeHUh?=
OAW-42	M1zDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nQbmlEPTB;MT6xPFMxPiEQvF2=	NYX6W3pbW0GQR1XS
DJM-1	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPtTWM2OD1zLkG5PFgyKM7:TR?=	NHGxbpZUSU6JRWK=
HH	NEPPfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTFwMkO4N\|Eh\|ryP	MmSxV2FPT0WU
LAMA-84	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTFwMkezPVQh\|ryP	M2\mSnNCVkeHUh?=
KNS-42	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHwfIhKSzVyPUGuN\|AzQTZizszN	MXLTRW5ITVJ?
NCI-H2052	NFHBSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr5cZg{UUN3ME2xMlMxPTB5IN88US=>	NYHydWx7W0GQR1XS
MLMA	NGPsbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFwM{K0NFch\|ryP	NXfKO5NTW0GQR1XS
NB12	M{HJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwM{W2N\|Yh\|ryP	M4qyOXNCVkeHUh?=
NCI-H1838	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTFwM{[zNFYh\|ryP	NXS1WppQW0GQR1XS
NCI-H526	Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjiTWM2OD1zLkO3PFU{KM7:TR?=	M1HVOXNCVkeHUh?=
LS-123	NXfh[mZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLNTWM2OD1zLkO5NFk1KM7:TR?=	MVrTRW5ITVJ?
HDLM-2	NVH3UlRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTFwM{myO\|Eh\|ryP	NWD1PW5XW0GQR1XS
MC-IXC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS1NZFlUUN3ME2xMlQzOzdzIN88US=>	M4rlSnNCVkeHUh?=
HCT-15	M2O3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXOwRVNxUUN3ME2xMlQ{ODZ6IN88US=>	MmC1V2FPT0WU
NCI-H596	NWHqbmE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFwNEWwOlEh\|ryP	NGnOV5BUSU6JRWK=
ZR-75-30	M3HUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPPcnl[UUN3ME2xMlQ4ODh{IN88US=>	MkfrV2FPT0WU
A704	M4f6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjqTWM2OD1zLk[2OVY{KM7:TR?=	M4HoeXNCVkeHUh?=
OVCAR-4	NEPIXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFwNkm2NFch\|ryP	MUHTRW5ITVJ?
SW1417	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\ydZVDUUN3ME2xMlczQDR7IN88US=>	NV\vbXpkW0GQR1XS
CAS-1	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFe2[4ZKSzVyPUGuO\|M6OzZizszN	NVLDRotNW0GQR1XS
IST-SL1	NEXWPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XqOGlEPTB;MT63PVc2QSEQvF2=	M17OT3NCVkeHUh?=
A253	NFm5ZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3CcJp{UUN3ME2xMlgzOjN7IN88US=>	MXnTRW5ITVJ?
EW-16	NVHPSId[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwOEK4O\|Uh\|ryP	Ml7BV2FPT0WU
SK-NEP-1	M{G3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTFwOE[5PFgh\|ryP	MlPHV2FPT0WU
NCI-H226	M3TZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTFwOEmzOVkh\|ryP	MUjTRW5ITVJ?
HOP-92	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1myPGlEPTB;MT65OlA6QSEQvF2=	MoHTV2FPT0WU
NCI-H441	NYH6fYtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjUTWM2OD1{LkCyN\|M4KM7:TR?=	NYG4WVlsW0GQR1XS
LU-139	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v5fGlEPTB;Mj6wN\|EyPCEQvF2=	NYj2cHhjW0GQR1XS
SJRH30	NWHZWWRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vDZWlEPTB;Mj6wOFI2OyEQvF2=	NVryVnk{W0GQR1XS
MG-63	NHHm[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1iweGlEPTB;Mj6xOFEyOSEQvF2=	NYe1[IQ2W0GQR1XS
NH-12	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHOdIZKSzVyPUKuNVUxODZizszN	NYW3Tm4xW0GQR1XS
NB7	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTjTGRKSzVyPUKuNVk3PzNizszN	NGDURW1USU6JRWK=
LB771-HNC	NWLVfXZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnmTWM2OD1{LkKwOVk2KM7:TR?=	M2rpN3NCVkeHUh?=
HCC1569	NHLLZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzuTWM2OD1{LkK0OVg{KM7:TR?=	NWLPeI9LW0GQR1XS
D-283MED	NVTw[JJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\jWWlEPTB;Mj6yOFc5OiEQvF2=	NIjXTmFUSU6JRWK=
J-RT3-T3-5	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;xTGlEPTB;Mj6yOVM2OSEQvF2=	NVHMdoR1W0GQR1XS
ATN-1	NImwbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3v4TWlEPTB;Mj6zN\|A5OiEQvF2=	M4PDXnNCVkeHUh?=
HCC1954	NHO4[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJwM{S0NFgh\|ryP	NHTpelVUSU6JRWK=
SCC-15	M1vBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTJwM{mzNVIh\|ryP	NX[1O\|Y4W0GQR1XS
COLO-668	NIDTPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmH1TWM2OD1{LkSzNkDPxE1?	NFKxXXlUSU6JRWK=
LB373-MEL-D	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nabGlEPTB;Mj61OFY4PyEQvF2=	M{LIfXNCVkeHUh?=
no-10	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moi3TWM2OD1{LkW0PVQ4KM7:TR?=	MlPCV2FPT0WU
HT-1197	NULDW3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvydVZuUUN3ME2yMlY{OTh6IN88US=>	NX\FOHVZW0GQR1XS
DU-145	NUTvUlhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGW5UYhKSzVyPUKuO\|kyPjJizszN	MkfuV2FPT0WU
SK-N-AS	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfBVopNUUN3ME2yMlg1Pjl{IN88US=>	MoW4V2FPT0WU
MOLT-4	NFrCeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHqxfY5KSzVyPUKuPFU{OjJizszN	MYXTRW5ITVJ?
EW-22	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HxOGlEPTB;Mj65Nlg1OSEQvF2=	NFjHT2tUSU6JRWK=
DB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4i4VGlEPTB;Mj65O\|c2QSEQvF2=	NULQUXpDW0GQR1XS
HL-60	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTNwMESzO\|Yh\|ryP	M1LNTnNCVkeHUh?=
SK-N-DZ	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\PfmlEPTB;Mz6wOVA4PSEQvF2=	M3\McXNCVkeHUh?=
NY	M17G[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH6TWM2OD1\|LkC4OVQzKM7:TR?=	NYDofVc5W0GQR1XS
T47D	NX;yV\|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTNwMUC1OVgh\|ryP	NInxWGNUSU6JRWK=
NCI-H2029	NYj3[JJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3KwU2lEPTB;Mz6yNlQ4PyEQvF2=	M4jyNXNCVkeHUh?=
KARPAS-299	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvmTWM2OD1\|LkK2NFI4KM7:TR?=	NX36dHhEW0GQR1XS
KM-H2	M{f2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;3bXRKSzVyPUOuN\|A3QCEQvF2=	NUnx[I9YW0GQR1XS
CHP-134	M3z6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTNwNEezPUDPxE1?	Mn:2V2FPT0WU
22RV1	NETBWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLVZWxKSzVyPUOuOFkyPjhizszN	NHz0TmJUSU6JRWK=
NB5	NWT0fogyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLuTWM2OD1\|LkWwOlg6KM7:TR?=	NEjsT3JUSU6JRWK=
CW-2	NWr4UpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTNwNUWzNVQh\|ryP	NIjVRodUSU6JRWK=
EFO-21	NXLBOY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnnTWM2OD1\|LkW2PVQh\|ryP	MWrTRW5ITVJ?
HuH-7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;uWFkyUUN3ME2zMlU5PDF2IN88US=>	MUTTRW5ITVJ?
ALL-PO	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3ZTWM2OD1\|Lk[yN\|M2KM7:TR?=	MoLVV2FPT0WU
EM-2	M3f1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W3dmlEPTB;Mz62PVAyOSEQvF2=	MXvTRW5ITVJ?
KLE	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLaVFBTUUN3ME2zMlc{ODJ7IN88US=>	MY\TRW5ITVJ?
NEC8	NVXwdWxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\tTWM2OD1\|LkmxPFA5KM7:TR?=	M4jxcnNCVkeHUh?=
KP-N-YN	NV;pTVJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFe4dZpKSzVyPUOuPVM1PzZizszN	MlrDV2FPT0WU
SK-MEL-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkCxTWM2OD12LkCzOVE5KM7:TR?=	Ml[wV2FPT0WU
CAL-54	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXJTWM2OD12LkC1PVEh\|ryP	MYXTRW5ITVJ?
MS-1	NIDOb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjwenpKSzVyPUSuNVYyPTVizszN	Ml20V2FPT0WU
NCI-H209	NFTxPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDBTWM2OD12LkK5PVk6KM7:TR?=	M1jBfXNCVkeHUh?=
NOMO-1	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTRwM{KxN\|Eh\|ryP	NVe3d4l{W0GQR1XS
RPMI-2650	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIi2eJhKSzVyPUSuN\|Y{OjdizszN	NFHoO4xUSU6JRWK=
NCI-H810	NH;tO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnxUmJKSzVyPUSuN\|k4OzZizszN	M{LDU3NCVkeHUh?=
Ca9-22	NH;sPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTRwNEW2PVEh\|ryP	NEn1S2JUSU6JRWK=
ES4	NYrpeHQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nqXmlEPTB;ND60O\|A6PSEQvF2=	NHzBS2VUSU6JRWK=
ES6	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrNbXBKSzVyPUSuOFk3PTdizszN	MXPTRW5ITVJ?
DMS-114	MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3uTWM2OD12LkW0OlkyKM7:TR?=	NFfTcnFUSU6JRWK=
ONS-76	MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXyVVJKSzVyPUSuOVc6PSEQvF2=	M3LqcnNCVkeHUh?=
K-562	NHHUSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLnOmhKSzVyPUSuO\|M5OTRizszN	MXvTRW5ITVJ?
MHH-NB-11	NFPWfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULPPWhbUUN3ME20Mlc2PDZzIN88US=>	M{D0[XNCVkeHUh?=
Calu-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\HOmlEPTB;ND63PFU1QCEQvF2=	NXzLUYc4W0GQR1XS
HT55	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3rd4V1UUN3ME20Mlg1PTR3IN88US=>	NXLiS\|NXW0GQR1XS
SK-N-FI	M3nje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTRwOEWwNFkh\|ryP	MULTRW5ITVJ?
ES1	NFPYOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTRwOE[wOVch\|ryP	NUGzTZNHW0GQR1XS
SF126	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnlTWM2OD12LkmzNVg1KM7:TR?=	NEC3XopUSU6JRWK=
ES5	M3rtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmW1TWM2OD13LkGyOFI4KM7:TR?=	MV\TRW5ITVJ?
LoVo	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\BSYVKSzVyPUWuNVU5PzFizszN	MkHMV2FPT0WU
SNU-387	M3GyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXhTWM2OD13LkOyN\|M6KM7:TR?=	MVfTRW5ITVJ?
C8166	NW\1U2VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LKOGlEPTB;NT6zOlM{QSEQvF2=	MWrTRW5ITVJ?
LS-1034	MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;I[FhiUUN3ME21MlQzOzB5IN88US=>	Ml;qV2FPT0WU
GR-ST	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn76TWM2OD13LkWyNlAyKM7:TR?=	NIHYe3VUSU6JRWK=
NCI-H1092	NWDNUGZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1e5R2lEPTB;NT63Nlg1OyEQvF2=	NFXTOmRUSU6JRWK=
647-V	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTLSW4{UUN3ME21Mlc1PzB4IN88US=>	MXLTRW5ITVJ?
EW-13	NXy3fYRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX31fWhnUUN3ME21Mlc3PjJ5IN88US=>	NYLSb2ppW0GQR1XS
KGN	Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\TZmVSUUN3ME22MlA6QTJzIN88US=>	M1nhfnNCVkeHUh?=
D-423MG	NEjHTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXpTI9rUUN3ME22MlQxOjh2IN88US=>	NVrzO2s2W0GQR1XS
ECC10	M{XZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfMO4w4UUN3ME23MlExOTBzIN88US=>	MWPTRW5ITVJ?
TE-5	M{js[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjzTWM2OD15LkSxNlk5KM7:TR?=	NGH4RoVUSU6JRWK=
P12-ICHIKAWA	NYHPPIRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjSTWM2OD15LkS1OVI{KM7:TR?=	Mn[5V2FPT0WU
NCI-H82	M{DqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\YTWM2OD15LkS1O\|AyKM7:TR?=	NV7ZfHpQW0GQR1XS
NCI-H1993	NIL4cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHsTWM2OD15LkizNFY{KM7:TR?=	MknkV2FPT0WU
RH-1	NIfaUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYH4SHNCUUN3ME23Mlg2OjR2IN88US=>	NFzUW21USU6JRWK=
SW948	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\1UWlEPTB;Nz65OlA1QSEQvF2=	MYnTRW5ITVJ?
CAL-33	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\POoxQUUN3ME23Mlk6QTN6IN88US=>	NW\qSYNlW0GQR1XS
U-266	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHP1c\|lKSzVyPUiuNVU4PzdizszN	M2izVnNCVkeHUh?=
CAL-72	M2O3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;aTWM2OD16LkKwN\|Ih\|ryP	NVnOPVNtW0GQR1XS
SNU-423	MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fpZWlEPTB;OT6zOlY3PiEQvF2=	MVLTRW5ITVJ?
KG-1	NXHnPXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoriTWM2OD17LkW4OFU3KM7:TR?=	M3zsOHNCVkeHUh?=
HCC1395	Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHpUpdKSzVyPUmuPVI{PTJizszN	NGnYTHFUSU6JRWK=
BE-13	M3fUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTFyLki4PVIh\|ryP	NV6wSWR[W0GQR1XS
MKN7	M4DaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDWTWM2OD1zMD65O\|Y2KM7:TR?=	NYjTXlJbW0GQR1XS
697	M{nSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;UcmtPUUN3ME2xNU4yPDd{IN88US=>	NFn4bo9USU6JRWK=
LU-135	NVLvc4NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr6V3ZoUUN3ME2xNU4zOzB5IN88US=>	MojXV2FPT0WU
ES7	M2rHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjBZ2h2UUN3ME2xNU4{OzF\|IN88US=>	MWnTRW5ITVJ?
SK-HEP-1	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXNW21KSzVyPUGxMlc3PDZizszN	Mn7UV2FPT0WU
BEN	NHq0XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NES4PWJKSzVyPUGxMlg2OSEQvF2=	NH\zZplUSU6JRWK=
NCI-H1770	NH\Dd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTF{LkGyOkDPxE1?	MkC0V2FPT0WU
SW13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfCcGxKSzVyPUGyMlE2PDFizszN	NWrxN41{W0GQR1XS
MZ1-PC	M3:0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF{LkW0OVIh\|ryP	MoXXV2FPT0WU
Mo-T	NFPMSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrJTWM2OD1zMj63OFIyKM7:TR?=	NFnUTYpUSU6JRWK=
HLE	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XJc2lEPTB;MUKuPFIyPSEQvF2=	MYjTRW5ITVJ?
RCC10RGB	NH;DdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoKxTWM2OD1zMz62O\|Eh\|ryP	NVPR[4tPW0GQR1XS
COLO-320-HSR	NETEN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDLUJNiUUN3ME2xN{44OzhzIN88US=>	MVzTRW5ITVJ?
BHT-101	NYTMb5p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkW0TWM2OD1zMz64N\|Q2KM7:TR?=	MnOzV2FPT0WU
OCUB-M	NIX2S3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\RVGlEPTB;MUSuNVYxOiEQvF2=	MmrZV2FPT0WU
MEG-01	M1nXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTF2LkO3NFgh\|ryP	MWnTRW5ITVJ?
RS4-11	NH7DZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nYVWlEPTB;MUSuO\|QzKM7:TR?=	NXHifFlGW0GQR1XS
MN-60	NXXlcJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTF2Lke4PVQh\|ryP	M4mxdHNCVkeHUh?=
NCI-H1304	M{WyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjm[4JKSzVyPUG1MlA1OjVizszN	Mn7EV2FPT0WU
Ramos-2G6-4C10	NGTJUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjKOFBsUUN3ME2xOU4xPThzIN88US=>	MkG5V2FPT0WU
NCI-H2342	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXP0V5NuUUN3ME2xOU4zODR2IN88US=>	M2PTbXNCVkeHUh?=
LAN-6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGmyRnJKSzVyPUG1MlQ1OTRizszN	Mmi4V2FPT0WU
JVM-2	M3X0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;lZ3A{UUN3ME2xOU42PzR6IN88US=>	NX3lNVZEW0GQR1XS
P30-OHK	NEPEO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTF4LkC2NVQh\|ryP	MonXV2FPT0WU
C-33-A	M2jsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPGdnVKSzVyPUG2MlYzOTRizszN	M4P4VnNCVkeHUh?=
RPMI-8866	NUHQTWk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rESWlEPTB;MU[uPFQ6PiEQvF2=	NHPublFUSU6JRWK=
NCI-H630	M3f3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3KO4JwUUN3ME2xOk45PTN5IN88US=>	M1j5bHNCVkeHUh?=
KYSE-140	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XEXWlEPTB;MUeuNlAzQCEQvF2=	NWLYRod2W0GQR1XS
T84	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;md2lEPTB;MUiuPFY6PSEQvF2=	NXPONY4yW0GQR1XS
KU-19-19	MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrofZNKSzVyPUG4Mlk3ODhizszN	M1WwbXNCVkeHUh?=
BALL-1	M1m4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r0ZmlEPTB;MUmuN\|M6QSEQvF2=	MlXZV2FPT0WU
Calu-6	M4jxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrCTWM2OD1zOT60PVIh\|ryP	NUDle5ZpW0GQR1XS
EGI-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTF7LkW5PEDPxE1?	MoezV2FPT0WU
MFH-ino	M1vNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTF7Lke0OVQh\|ryP	NGrneFdUSU6JRWK=
GB-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXBfVJKSzVyPUKwMlM2OzVizszN	NXnYfWw3W0GQR1XS
NCI-H1693	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzUTWM2OD1{MD62OVA2KM7:TR?=	MojhV2FPT0WU
SW1116	M1vh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjScYFpUUN3ME2yNE46OzZ{IN88US=>	M{DpOnNCVkeHUh?=
H-EMC-SS	M3fH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTJ{LkC0OUDPxE1?	MXrTRW5ITVJ?
D-502MG	M4DlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M160bmlEPTB;MkKuPFI3OSEQvF2=	Mlq5V2FPT0WU
IA-LM	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Hpb2lEPTB;MkOuNlQ6OyEQvF2=	M1zjRXNCVkeHUh?=
SW1463	NV6yUmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\JWWVKSzVyPUKzMlc6KM7:TR?=	M4q3XXNCVkeHUh?=
JAR	NXrlTYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nTRmlEPTB;MkSuN\|I6OyEQvF2=	NGq4bpRUSU6JRWK=
HT	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7a[5BKSzVyPUK0MlQ4PTNizszN	NGHifWZUSU6JRWK=
LCLC-103H	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETuO4VKSzVyPUK0Mlg1PDlizszN	MlKyV2FPT0WU
SNU-449	M1f1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJ2Lki3OFEh\|ryP	NYjZcoVbW0GQR1XS
KE-37	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLLTWM2OD1{NT6wPVI5KM7:TR?=	MnTTV2FPT0WU
NCI-H1623	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnhOXBlUUN3ME2yO{4yOzB\|IN88US=>	NIDpNnlUSU6JRWK=
MOLT-13	NUn0UolFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTJ5LkO1NVYh\|ryP	MkfiV2FPT0WU
COLO-741	NYDhb3ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPEN4gxUUN3ME2zNU4{OzN\|IN88US=>	MWjTRW5ITVJ?
NB6	NYfDO4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkO5TWM2OD1\|Mj6yPFc3KM7:TR?=	NIPu[2hUSU6JRWK=
MOLT-16	Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjPWY1YUUN3ME2zN{4xODV3IN88US=>	M3rYeHNCVkeHUh?=
IST-MES1	NXPkfGgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHFPIZNUUN3ME2zOE4xPTRzIN88US=>	NH7nWHpUSU6JRWK=
A4-Fuk	NFizZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq0WWpKSzVyPUO1MlA3PiEQvF2=	MkDwV2FPT0WU
CAL-85-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXUTWM2OD1\|NT6yPFE4KM7:TR?=	NILkeZNUSU6JRWK=
CCRF-CEM	NWPBV3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTN5LkG1N\|Yh\|ryP	NHu3bG9USU6JRWK=
HAL-01	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTN6LkS4PFkh\|ryP	MoS1V2FPT0WU
HEL	Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XodWlEPTB;NEOuN\|QxQSEQvF2=	MWPTRW5ITVJ?
EW-1	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW[z[3NrUUN3ME20N{41PzZ6IN88US=>	MYXTRW5ITVJ?
MDA-MB-231	NYHUZmJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTR3LkGxPVkh\|ryP	M13ZVHNCVkeHUh?=
ABC-1	Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1f6UmlEPTB;NE[uPFU{QCEQvF2=	M3TTfnNCVkeHUh?=
NCI-H446	NFvySZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTR6LkWwOVgh\|ryP	MUTTRW5ITVJ?
MHH-PREB-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPJPYFKSzVyPUS5MlYxODdizszN	M3jUU3NCVkeHUh?=
DOHH-2	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonZTWM2OD12OT62OlU3KM7:TR?=	NEXHO2NUSU6JRWK=
GCT	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTR7Lk[5O\|Yh\|ryP	MYTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products4

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)